BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36056633)

  • 21. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
    Sun Y; Sun Q; Tian J; He X
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
    Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
    Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis.
    Michalaki M; Bountouris P; Roupas ND; Theodoropoulou A; Agalianou N; Alexandrides T; Markou K
    Hormones (Athens); 2016 Oct; 15(4):511-517. PubMed ID: 28222412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
    Dai P; Zhao W; Zheng X; Luo H; Wang X
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
    Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
    JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report.
    Thewjitcharoen Y; Krittiyawong S; Butadej S; Nakasatien S; Polchart S; Junyangdikul P; Kanchanapituk A; Himathongkam T
    Medicine (Baltimore); 2020 Apr; 99(16):e19892. PubMed ID: 32312017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
    Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer.
    Zhang X; Liu JR; Mu ZZ; Cheng XQ; Lin YS
    J Clin Endocrinol Metab; 2023 May; 108(6):1330-1337. PubMed ID: 36567646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
    Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
    BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
    Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
    J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
    Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
    Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
    Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.